普拉克索对帕金森病患者轻度认知功能障碍的影响(3)
[5]Aarsland D，Br？nnick K，Larsen JP，et al.Cognitive impairment in incident，untreated Parkinson disease The Norwegian ParkWest Study[J].Neurology，2009，72(13)：1121-1126.
[6]Hely MA，Reid WG，Adena MA，et al.The Sydney multicenter study of Parkinson's disease：the inevitability of dementia at20 years[J].Mov Disord，2008，23(6)：837-844.
[7]Pfeiffer HC ，Lokkegaard A，Zoetmulder M，et al.Cognitiv pairment in early-stage non-demented Parkinson′s disease patients[J].Acta Neurol Scand，2014，129(5)：307-318.
[8]符丽艳，刘诗翔，王文富.帕金森病早期病理變化及临床表现研究[J].疑难病杂志，2013，12(1)：72-73.
[9]Kehagia AA，Barker RA，Robbins TW.Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease[J].Lancet Neurol，2010，9(12)：1200-1213.
[10]Domell？f ME，Elgh E，Forsgren L.The relation between cognitionand motor dysfunction in drug-naive newly diagnosed patients with Parkinson′s disease[J].Mov Disord，2011，26(12)：2183-2189.
[11]Cools R.Dopaminergic modulation of congnitive function implications for L-DOPA treatment in Parkinson′s disease[J].Neurosci Biohehav Rev，2006，30(1)：1-23.
[12]Ravina B，Putt M，Siderowf A，et al.Donepezil for dementia in Parkinson's diseas ：a randomized，double blind，placebo controlled，crossover study[J].J Nuerol Neurosurg Psychiatry，2005，76(7)：934-939.
[13]Parkison Study Group.Pramipexole in levodopa-treated Parkinson disease patients of African， Asian， and Hispanic heritage[J].Clin Neuropharmacol，2007，30(2)：72-85.
[14]Eisenreich W，Sommer B，Hartter S，et al.Pramipexole extended release： a novel treatment option in Parkinson's disease[J].Parkinsons Dis. 2010，19：612-619.
编辑/赵恒德
Key words：Parkinson's disease；Mild cognitive dysfunction；Pramipexole；Piribedil, 百拇医药(韦春英 韩敏 莫颖敏 罗文静 刘波)
[6]Hely MA，Reid WG，Adena MA，et al.The Sydney multicenter study of Parkinson's disease：the inevitability of dementia at20 years[J].Mov Disord，2008，23(6)：837-844.
[7]Pfeiffer HC ，Lokkegaard A，Zoetmulder M，et al.Cognitiv pairment in early-stage non-demented Parkinson′s disease patients[J].Acta Neurol Scand，2014，129(5)：307-318.
[8]符丽艳，刘诗翔，王文富.帕金森病早期病理變化及临床表现研究[J].疑难病杂志，2013，12(1)：72-73.
[9]Kehagia AA，Barker RA，Robbins TW.Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson's disease[J].Lancet Neurol，2010，9(12)：1200-1213.
[10]Domell？f ME，Elgh E，Forsgren L.The relation between cognitionand motor dysfunction in drug-naive newly diagnosed patients with Parkinson′s disease[J].Mov Disord，2011，26(12)：2183-2189.
[11]Cools R.Dopaminergic modulation of congnitive function implications for L-DOPA treatment in Parkinson′s disease[J].Neurosci Biohehav Rev，2006，30(1)：1-23.
[12]Ravina B，Putt M，Siderowf A，et al.Donepezil for dementia in Parkinson's diseas ：a randomized，double blind，placebo controlled，crossover study[J].J Nuerol Neurosurg Psychiatry，2005，76(7)：934-939.
[13]Parkison Study Group.Pramipexole in levodopa-treated Parkinson disease patients of African， Asian， and Hispanic heritage[J].Clin Neuropharmacol，2007，30(2)：72-85.
[14]Eisenreich W，Sommer B，Hartter S，et al.Pramipexole extended release： a novel treatment option in Parkinson's disease[J].Parkinsons Dis. 2010，19：612-619.
编辑/赵恒德
Key words：Parkinson's disease；Mild cognitive dysfunction；Pramipexole；Piribedil, 百拇医药(韦春英 韩敏 莫颖敏 罗文静 刘波)
参见：首页 > 医疗版 > 疾病专题 > 神经内科 > 锥体外系疾病 > 帕金森病